Patents by Inventor Guiying Li

Guiying Li has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Benzimidazole and pyridylimidazole derivatives
    Publication number: 20030069257
    Abstract: This invention relates to benzimidazoles, pyridylimidazoles and related bicyclic heteroaryl compounds, all of which may be described by of Formula I 1
    Type: Application
    Filed: December 21, 2001
    Publication date: April 10, 2003
    Inventors: Guiying Li, John M. Peterson, Pamela Albaugh, Kevin S. Currie, Guolin Cai, Linda M. Gustavson, Kyungae Lee, Alan Hutchison, Vinod Singh, George D. Maynard, Jun Yuan, Ling Hong Xie, Manuka Ghosh, Nian Liu, George P. Luke, Scott Mitchell, Martin Patrick Allen, Spiros Liras
  • RNase L activators and antisense oligonucleotides effective to treat telomerase-expressing malignancies
    Patent number: 6468983
    Abstract: The present invention relates to chimeric molecules comprising an oligonucleotide complementary to a region of the ribonucleotide component of telomerase attached to an activator of RNase L (“activator-antisense complex”) which specifically cleaves the ribonucleotide portion of a telomerase enzyme. The present invention relates to methods of inhibiting telomerase enzymatic activity with activator-antisense complexes targeted to the RNA component of telomerase. The present invention further relates to methods of treating malignant neoplastic disease, wherein the malignant cells contain a telomerase activity that is necessary for the growth of the malignant cells.
    Type: Grant
    Filed: February 3, 1998
    Date of Patent: October 22, 2002
    Assignees: The Cleveland Clinic Foundation, The United States of America as represented by the Department of Health and Human Services
    Inventors: Robert H. Silverman, Seiji Kondo, John K. Cowell, Guiying Li, Paul F. Torrence
  • RNASE L ACTIVATORS AND ANTISENSE OLIGONUCLEOTIDES EFFECTIVE TO TREAT TELOMERASE- EXPRESSING MALIGNANCIES
    Publication number: 20010007902
    Abstract: The present invention relates to chimeric molecules comprising an oligonucleotide complementary to a region of the ribonucleotide component of telomerase attached to an activator of RNase L (“activator-antisense complex”) which specifically cleaves the ribonucleotide portion of a telomerase enzyme. The present invention relates to methods of inhibiting telomerase enzymatic activity with activator-antisense complexes targeted to the RNA component of telomerase. The present invention further relates to methods of treating malignant neoplastic disease, wherein the malignant cells contain a telomerase activity that is necessary for the growth of the malignant cells.
    Type: Application
    Filed: February 3, 1998
    Publication date: July 12, 2001
    Inventors: ROBERT H. SILVERMAN, SEIJI KONDO, JOHN K. COWELL, GUIYING LI, PAUL F. TORRENCE
  • RNase L activators and antisense oligonucleotides effective to treat RSV infections
    Patent number: 6214805
    Abstract: The present invention relates to methods of inhibiting infection by RNA viruses with complexes of an activator of RNase L and an oligonucleotide that is capable of binding to the genome, antigenome or mRNAs of a negative strand RNA virus to specifically cleave the genomic or antigenomic RNA strand of the virus. In accordance with the present invention, the methods and complexes of the invention may be applied to target any negative strand RNA virus. The invention in one embodiment relates to a covalently linked complex of an oligonucleotide that is capable of binding to the genomic or antigenomic template RNA strand of a negative strand RNA virus and/or binding to an mRNA of a viral protein (an “antisense oligonucleotide”) coupled to an activator of RNase L. In a preferred embodiment of the present invention, the oligonucleotide component of the complex is complementary to a region of the viral genomic RNA strand characterized by repeated or consensus sequences.
    Type: Grant
    Filed: November 3, 1997
    Date of Patent: April 10, 2001
    Assignees: The United States of America as represented by the Department of Health and Human Services, The Cleveland Clinic Foundation
    Inventors: Paul F. Torrence, Robert Hugh Silverman, Nick Mario Cirino, Guiying Li, Wei Xiao, Mark R. Player
  • RNase L activators and antisense oligonucleotides effective to treat RSV infections
    Patent number: 5998602
    Abstract: The invention concerns a compounds and methods for treating infection with Respiratory Syncytial Virus. The compounds comprise an antisense portion, which is complementary to a normally single stranded portion of the RSV antigenomic strand (the mRNA strand), a linker and a oligonucleotide activator of RNase L, a ubiquitous non-specific RNase. The method comprised forming a complex of an activated RNase L and the antisense molecule. The application teaches methods of determining which portions of the RSV antigenomic strand are normally single-stranded. The application teaches that an antisense oligonucleotide having the sequence of residues 8281-8299 of the RSV genome is particularly useful to practice the invention and provides in vitro results superior to those obtainable with the conventional drug of choice, ribavirin.
    Type: Grant
    Filed: February 14, 1997
    Date of Patent: December 7, 1999
    Assignee: The Cleveland Clinic Fouindation and Government
    Inventors: Paul F. Torrence, Robert Hugh Silverman, Nick Mario Cirino, Guiying Li, Wei Xiao